Search

Find exactly what you’re looking for.

Showing 1-7 of 7 results

January 26, 2024 - With AI poised to reshape the practice of law and businesses in every industry, Saul Ewing is pleased to partner with the ABA’s Intellectual Property Litigation Committee in forming the AI Subcommittee. The AI Subcommittee will monitor legal and technological developments in this...

On May 18, 2023, the Supreme Court unanimously affirmed the Federal Circuit's decision, Amgen Inc. v. Sanofi, 987 F.3d 1080 (Fed. Cir. 2021), that the claims of two of Amgen's patents were invalid for lack enablement. The involved patents, US 8,829,165 and US 8,859,741, are directed to monoclonal...

The FTC has announced the annual updates to the Hart-Scott-Rodino (“HSR”) size thresholds, fees and the daily penalty for HSR violations. The updated thresholds and fees were published in the Federal Register on January 26, 2023 and will take effect on February 27, 2023. See Federal Register...

LATEST UPDATE The FTC has voted to extend the public comment period on its proposed rule to ban employers from imposing non-competes on their workers, and will now be accepting comments on the proposed rule until April 19, 2023. Comments can still be submitted in either writing or online using the...

The use of artificial intelligence (AI) to create works of art and inventions raises interesting legal challenges to the protection of intellectual property (IP). The plain language of the Copyright Act and Patent Act present obstacles to inventors and artists who may use or be AI systems. Recent...

Saul Ewing LLP, a full-service law firm with attorneys in 16 offices, today announced that 59 attorneys from the Firm received the distinguished honor of being recognized for legal excellence and client service by Chambers USA 2022. Several of the Firm’s practice areas also earned high rankings...

Washington, D.C., November 24, 2021 – Saul Ewing LLP served as counsel to Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) in the successful completion today of its previously announced $450 million acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). The acquisition strengthens Supernus'...

For More Information